MiMedx Group, Inc.

MiMedx Group, Inc.

MDXGNYSE / NASDAQHealthcareSmall cap

$3.05-$0.06 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$563.0M
P/E
11.6x
EV / EBITDA
5.3x
Revenue
$418.6M
Net margin
11.6%
ROCE
22.9%

-53.4% over the last year

MiMedx Group, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-27.9%
3M
-29.1%
6M
-19.5%
1Y
-53.4%
5Y
-60.5%

52-week range

Day change -$0.06 (-1.9%) from $3.11 to $3.05 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MDXG, bought on each weekday since 2021.

News & filings

What MiMedx Group filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 63.3 times interest costs.

Concerns (1)

  • The price is 26.0% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.

Read moreShow less

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Sector
Healthcare
Shares outstanding
147.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$563.0M
P/E
11.6x
P/B
2.2x
EV / EBITDA
5.3x
EV / Sales
1.0x
P/S
1.3x
52-week high
$7.25
52-week low
$3.05

Profitability

Operating margin
15.3%
Net margin
11.6%
EBITDA margin
18.8%
ROE
18.9%
ROCE
22.9%
ROIC
43.2%
ROA
14.2%
Asset turnover
1.22

Growth

Revenue
$418.6M
Revenue growth, 1Y
20.0%
Revenue CAGR, 3Y
16.1%
Net profit growth, 1Y
14.5%
Free cash flow
$73.0M

Solvency

Current ratio
4.32
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
1.52
Cash / Market cap
29.5%

Where the revenue went

Of every $100 of FY2025 revenue, $12 was left as net income.

MiMedx Group, Inc. income statement flow, FY2025
MiMedx Group, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$73.0M
RevenueGross profit$345.6M
Gross profitResearch and development$15.1M
Gross profitSelling, general and administrative$266.2M
Gross profitOther operating expenses$440.0k
Gross profitOperating income$63.9M
Operating incomePretax income$63.9M
Interest and other incomePretax income$2.4M
Pretax incomeTax and other$17.7M
Pretax incomeNet income$48.6M

Revenue and net profit

Revenue grew 20.0% in FY2025; net profit is the dashed line.

MiMedx Group, Inc. revenue and net profit by fiscal year
MiMedx Group, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$267.8M-$30.2M
FY2023$321.5M$58.2M
FY2024$348.9M$42.4M
FY2025$418.6M$48.6M

Cash flows

FY2025: $74.0M from operations, $73.0M free after investment (dashed).

MiMedx Group, Inc. operating and free cash flow by fiscal year
MiMedx Group, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$17.9M-$19.4M
FY2023$26.8M$24.8M
FY2024$66.2M$64.5M
FY2025$74.0M$73.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$418.6M+20.0%1Y
EBITDA
$78.8M+20.5%1Y
Net profit
$48.6M+14.5%1Y
Cash from operations
$74.0M+11.8%1Y
Free cash flow
$73.0M+13.1%1Y
Revenue CAGR, 3Y
16.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$418.6M$78.8M$48.6M$73.0M18.9%+20.0%+14.5%

Monthly returns

Month-by-month returns of MDXG across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$342.6M
Liabilities$86.1M
Equity$256.6M
Paid-in capital$299.1M
Retained earnings-$42.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MDXG highlighted.

P/E against peers

MDXG trades at 11.6x earnings against a peer median of -6.4x.

EV / Sales, for the companies without earnings

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
MiMedx Group, Inc.MDXGthis company$563.0M11.6x2.2x18.9%5.3x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
Rigel Pharmaceuticals, Inc.RIGL$559.7M1.5x1.4x93.8%4.4x
Ironwood Pharmaceuticals, Inc.IRWD$559.7M23.3x-2.1x-9.2%9.0x
Cytek Biosciences, Inc.CTKB$559.2M-8.4x1.6x-19.5%-28.3x
Cerus CorporationCERS$559.0M—8.7x-24.3%—
NeuroPace, Inc.NPCE$556.4M-25.9x29.2x-112.8%-50.2x
Fulgent Genetics, Inc.FLGT$553.8M-9.2x0.5x-5.4%-11.2x
Peer median—-6.4x2.1x-14.3%-6.4x

Year-to-date ROI

MDXG since 1 January, against earlier years.

Historical volatility

MDXG's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

MiMedx Group, Inc. operating margin by fiscal year
MiMedx Group, Inc. operating margin by fiscal year
DateOperating margin
FY2022-5.5%
FY202311.5%
FY202417.0%
FY202515.3%
LineFY2025
Cost of revenueCost Of Revenue$73.0M
Gross profitGross Profit$345.6M
Operating expensesOperating Expense$281.7M
Research and developmentResearch And Development$15.1M
Selling, general and administrativeSelling General And Administration$266.2M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$440.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$440.0k
Amortization$440.0k
Amortisation of intangiblesAmortization Of Intangibles Income Statement$440.0k
Total expensesTotal Expenses$354.7M
Pretax incomePretax Income$66.3M

Learn while you research

Academy chapters picked for MiMedx Group, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 11.6 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →